Abstract 166 Table 1

Characteristics		All patients n=42 (%)
Operation duration [minutes] n= 35		Median 280 (180-458)
Operative approach	Laparoscopy	24 (57.1%)
	Open surgery	18 (42.9%)
Nerve-sparing technique	bilateral	40 (95.23%)
	unilateral	2 (4.76%)
Lymph node resection	Only sentinel	2 (4.76%)
	Pelvic	25 (59.5%)
	Pelvic and paraaortic	15 (35.7%)
Median number of resected pelvic lymph nodes		44.9 (12-89)
Median number of resected paraaortic lymph nodes		16.7 (5-60)
Cases with affected pelvic lymph nodes (range) n= 40		20 (47.6%) (1-45)
Cases with affected paraaortic lymph nodes (range) n= 15		4 (9.5%) (1-16)
Parametrial infiltration		22 (52.4%)
Vaginal infiltration		11 (26.2%)
Hospital stay [days] Median (range)		10.8 (4-19)
Estimated blood loss [ml] Median (range) n= 22		97.7 (50-450) ml
Complications (Grade according to Clavien-Dindo classification)	Ureter necrosis (GIII)	2 (4.76%)
	Urinary tract infections (GII)	3 (7.14%)
	Sub-ileus (GII)	1 (2.38%)
	Lymphatic oedema (GII)	3 (7.14%)
	Wound dehiscence (GIII)	1 (2.38%)
	Numbness the upper thigh (GI)	3 (7.14%)
	Nausea and vomiting (GI)	5 (11.9%)
	Radiotherapy	Advised 2 (4.76%) Done 1 (2.38%)
	Radiochemotherapy	Advised 21 (50%) Done 17 (40.47%)
	Chemotherapy	1 (2.38%)
Bladder function	Complete healing according to protocol	38 (90.5%)
	Prolonged healing for 2 weeks	3 (7.14%)
	Persistence of impaired sensation	1 (2.38%)
Recurrences	Paraaortic relapse	1 (2.38%)
	Pelvic sidewall	2 (4.76%)
	Inguinal relapses	1 (2.38%)
	Vaginal vault	0
	All recurrences	4 (9.5%)

comprehensive understanding of the precise entire anatomy of paracolpium is feasible and applicable even in locally advanced tumors, with good functional results and convincing short-term oncologic outcomes.

IGCS20_1153

167 REFLEX METHYLATION TESTING IN ENDOMETRIAL CANCER: A SINGLE CENTRE RETROSPECTIVE STUDY

M Honner*, N Siddique, R McBain, F Chan, O McNally. *The Royal Women's Hospital, Australia*

10.1136/ijgc-2020-IGCS.145

Introduction Looking for evidence of microsatellite instability (MSI) through immunohistochemistry (IHC) for loss of staining for mismatch repair (MMR) proteins MLH1, PMS2, MSH2 and MSH6 at the time of histopathological examination of endometrial cancers is increasingly becoming standard of care; to guide recurrent disease treatment and identify

patients whose cancers may be the result of a genetic mutation eg. Lynch syndrome. Identification of IHC as a surrogate for MSI is employed in many centres. Currently patients need referral to a Familial Cancer Centre (FCC) for counselling prior to further tumour testing including methylation testing, which is more likely to be responsible for loss of staining for MLH1 and PMS2.

Aim Audit the practice of IHC for MMR proteins and identify efficiencies to the FCC referral pathway using reflex methylation testing.

Methods Patients diagnosed with endometrial cancer over a five-year period were included. Data was retrieved from the in-house clinical database, FCC database and patient histories and included: completeness of IHC for MMR, type of MMR loss of expression, proportion of referrals to FCC, number of genetic mutations identified, proportion of MLH1 and PMS2 as result of methylation.

Results Loss of staining for MMR was found in 20% of endometrial cancers. This was for MSH2/MSH6 in 1.7% and 19% for MLH1/PMS2. 95% of cases with loss of MMR proteins MLH1/PMS2 were found to be due to methylation and <5% had a germline mutation. 60% had a germline mutation in MSH2/MSH6.

Conclusion IHC for MMR at the time of endometrial cancer diagnosis is increasingly practiced. This study highlights the importance of reflex methylation testing in cases of MLH1 and PMS2 thus reducing the burden on patients and FCCs where hitherto methylation testing is not ordered before referral.

IGCS20_1154

168 ENDOMETRIAL AND COLON CANCER RISK ASSESSMENT IN WOMEN WITH LYNCH SYNDROME: PROVIDER COMFORT, KNOWLEDGE, AND CURRENT PRACTICE

R Bramblet*, A Weaver, C Langstraat, S Maurer, C Swanson, M Sherman, J Kiesel, M Wick, J Bakkum-Gamez. *Mayo Clinic, USA*

10.1136/ijgc-2020-IGCS.146

Objective Women with Lynch Syndrome (LS) experience a life-time risk of endometrial (EC) and colon (CC) cancer of up to 57%, and the risk is approximately equal for each LS gene. Our objective was to determine knowledge of EC and CC risks, screening guidelines, and management recommendations among healthcare providers caring for women with LS.

Methods An anonymous survey was sent to providers in primary care, ob/gyn, gynecologic oncology, gastroenterology, and

Abstract 168 Table 1 Counseling by 77 respondents who report they currently care for women with LS

Survey Item	Endometrial Cancer (EC)	Colon Cancer (CC)
Counsel on increased risk of EC or CC	65 (84%)	77 (100%)
Recommend screening/early detection options for EC or CC	44 (57%)	75 (97%)
Offer screening consistent with national guidelines for EC or CC	23 (30%)	43 (56%)
Do not recommend screening for EC or CC	8 (10%)	0 (0%)
Most concerned for EC or CC to occur first	15 (20%)	48 (62%)
Recommend risk reducing hysterectomy	33 (43%)	NA